comparemela.com

Latest Breaking News On - Clinical trial registry - Page 1 : comparemela.com

Swiss and Indian Pharma Giants Locked in Big War; Land at DCGI Door Over Breast Cancer Drug | Exclusive

Swiss pharmaceutical firm Roche has sounded alarm against clinical trials conducted by Zydus Lifesciences on its biologic drug Perjeta, a widely-used breast cancer treatment. The Swiss company has filed a complaint against the Indian drug maker over alleged critical gaps in the clinical trial of a drug originally developed by Roche

Rakuten Medical to Start a Global Phase 3 Trial of Alluminox™ Treatment using ASP-1929 for Recurrent Head and Neck Cancer in India

Business News | Rakuten Medical to Start a Global Phase 3 Trial of Alluminox Treatment Using ASP-1929 for Recurrent Head and Neck Cancer in India

Get latest articles and stories on Business at LatestLY. Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization (CDSCO) to conduct its global, pivotal Phase 3 clinical trial (ASP-1929-301/ClinicalTrials.gov Identifier: NCT03769506) evaluating Alluminox treatment (photoimmunotherapy) using ASP-1929 in patients with locoregional, recurrent head and neck squamous cell carcinomas (HNSCC) in India, and the registration of clinical trial information with the Clinical Trial Registry of India (CTRI) has been completed (CTRI Identifier: CTRI/2023/05/052728). The study sites will include several leading medical institutions in India such as the Tata Memorial Centre and Narayana Health, and the treatment will be administered to enrolled patient

Rakuten Medical to Start a Global Phase 3 Trial of Alluminox™ Treatment Using ASP-1929 for Recurrent Head and Neck Cancer in India

Rakuten Medical, a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization CDSCO to conduct its global, pivotal Phase 3 clinical trial ASP-1929-301ClinicalTrials.gov Identifier NCT03769506 evaluating Alluminox treatment photoimmunotherapy using ASP-1929 in patients with locoregional, recurrent head and neck squamous cell carcinomas HNSCC in India, and the registration of clinical trial information with the Clinical Trial Registry of India CTRI has been completed CTRI Identifier CTRI202305052728.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.